bezafibrate has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (54.55) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 1 (4.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Espinosa, J; Fanghänel, G; Hernández, G; Macías, G; Martínez, L; Morales, M; Olivares, D; Sánchez, L; Valdés, E | 1 |
| Eliav, O; Friedlander, Y; Leitersdorf, E; Pfister, P; Schurr, D | 1 |
| Eliav, O; Leitersdorf, E; Muratti, EN; Peters, TK | 1 |
| Armstrong, VW; Beil, FU; Eskötter, H; Greten, H; Keller, C; Klör, HU; Schneider, J; von Hodenberg, E; Weidinger, G; Weisweiler, P | 1 |
| Dann, EJ; Eisenberg, S; Eliav, O; Leitersdorf, E; Meiner, V; Muratti, EN; Peters, TK; Sehayek, E; Stein, Y | 1 |
| Leitersdorf, E; Muratti, EN; Peters, TK | 1 |
| Jokubaitis, LA | 1 |
| Eagles, CJ; Kendall, MJ; Maxwell, S | 1 |
| Hailer, S; Keller, C; Pogarell, O; Wolfram, G | 1 |
| Eagles, CJ; Kendall, MJ | 1 |
| Ganotakis, ES; Jagroop, IA; Mikhailidis, DP; Papadakis, JA; Winder, AF | 1 |
| Hemsley, D; Wray, R | 1 |
| Hannak, M; Lüscher, TF; Noll, G; Spieker, LE | 1 |
| Boschetti, C; Cofrancesco, E; Cortellaro, F; Cortellaro, M; Mancini, M; Mariani, M; Paoletti, R | 1 |
| Borgnino, C; Mancini, M; Mariani, M; Paoletti, R; Pauciullo, P | 1 |
| Hirschfield, G | 1 |
| Akahane, M; Aoyagi, S; Awata, T; Hayashi, K; Inoue, I; Itoh, F; Katayama, S; Komoda, T; Kusama, H; Mastunaga, T; Tazawa, S | 1 |
| Bortolini, M; Farnier, M; Freudenreich, MO; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Dejager, S; Farnier, M; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Hidaka, H; Hongo, M; Ikeda, U; Kinoshita, O; Kumazaki, S; Mawatari, E; Takahashi, M; Tsutsui, H; Yazaki, Y | 1 |
| Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M | 1 |
1 review(s) available for bezafibrate and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
14 trial(s) available for bezafibrate and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Tolerance; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Middle Aged; Safety; Triglycerides | 1995 |
High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Delayed-Action Preparations; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Heterozygote; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Longitudinal Studies; Placebos; Safety; Triglycerides | 1995 |
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Artery Disease; Creatine Kinase; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Male; Middle Aged; Patient Compliance; Placebos; Safety; Triglycerides | 1995 |
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipids; Male; Middle Aged; Treatment Outcome | 1994 |
Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heterozygote; Humans; Hyperlipoproteinemia Type II; Indoles; Male; Middle Aged; Myositis; Placebos; Safety; Single-Blind Method; Triglycerides | 1994 |
Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Cohort Studies; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lipids; Lipoproteins; Male; Middle Aged; Retrospective Studies; Time Factors | 1994 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic subjects.
Topics: Adult; Analysis of Variance; Bezafibrate; Cross-Over Studies; Double-Blind Method; Energy Metabolism; Exercise; Fatty Acids, Monounsaturated; Fatty Acids, Nonesterified; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Oxidation-Reduction | 1996 |
Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Blood Protein Electrophoresis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Indoles; Lipoproteins, HDL; Male; Middle Aged | 1996 |
The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects.
Topics: Adrenergic beta-Antagonists; Adult; Ammonia; Analysis of Variance; Anticholesteremic Agents; Atenolol; Bezafibrate; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Energy Metabolism; Exercise; Fatigue; Fatty Acids, Monounsaturated; Fatty Acids, Nonesterified; Female; Fluvastatin; Heart Rate; Humans; Hypolipidemic Agents; Indoles; Lactic Acid; Lipids; Male; Oxygen Consumption; Triglycerides | 1997 |
Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Middle Aged | 2000 |
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Trea
Topics: Adult; Aged; Bezafibrate; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Tissue Plasminogen Activator; Treatment Outcome | 2000 |
Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study).
Topics: Adult; Aged; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Indoles; Male; Middle Aged; Safety; Treatment Outcome; Triglycerides | 2000 |
Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study.
Topics: Aged; Aorta; Bezafibrate; Blood Flow Velocity; Coronary Artery Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Linear Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pulsatile Flow; Risk Factors; Treatment Outcome | 2008 |
8 other study(ies) available for bezafibrate and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibric Acids; Fluvastatin; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged; Pilot Projects; Treatment Outcome | 1999 |
Statin + fibrate combination therapy--fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Topics: Bezafibrate; Cholesterol; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Treatment Outcome; Triglycerides; Vascular Diseases | 1999 |
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal.
Topics: Bezafibrate; C-Reactive Protein; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Models, Statistical | 2001 |
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.
Topics: Anticholesteremic Agents; Bezafibrate; Blotting, Western; CCAAT-Enhancer-Binding Proteins; Cell Nucleus; DNA-Binding Proteins; DNA, Complementary; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Gene Library; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Ligands; Liver; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Muscle, Skeletal; NF-kappa B; Nuclear Proteins; Protein Structure, Tertiary; Pyridines; Quinolines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; Sequence Analysis, DNA; Sterol Regulatory Element Binding Protein 1; Trans-Activators; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection | 2002 |
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged | 2003 |
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Age Factors; Bezafibrate; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Retrospective Studies; Sex Factors; Treatment Outcome; Triglycerides | 2003 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
[Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm].
Topics: Anticholesteremic Agents; Atorvastatin; Bezafibrate; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pyrroles | 2012 |